Page 223 - Drug Class Review
P. 223
Drug Effectiveness Review Project
memantine placebo 72% 78% 11.9% 9.4% Significant differences favoring placebo: confusion 7.9% vs. 2% (P = 0.01); headache 6.4% vs. 2.5% (P = 0.09); significant differences favoring MEM: diarrhea 4.5% vs. 8.5% (P = NR) and fecal incontinence Post randomization exclusions: NR Overall loss to follow-up: 20% Loss to follow-up differential high: Yes placebo memantine 25.4% 14.9% 12.4% 7.4% Page 142 of 205
2% vs. 5% (P = NR) ITT: Yes Yes Yes NR Fair
Final Report Update 1 Authors: Tariot et al. Year: 2004 ADVERSE EVENTS: Overall adverse effects reported: Agitation • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
